Harbor Capital Advisors, Inc. Uni Qure N.V. Transaction History

Harbor Capital Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$4.82 - $6.93 $19,198 - $27,602	3,983 Added 12.9%	34,866 $181,000
Q4 2023 Jan 08, 2024	BUY	$5.63 - $8.27 $30,340 - $44,567	5,389 Added 21.14%	30,883 $209,000
Q3 2023 Oct 20, 2023	BUY	$6.71 - $11.83 $25,833 - $45,545	3,850 Added 17.79%	25,494 $171,000
Q2 2023 Jul 11, 2023	BUY	$11.12 - $22.2 $22,184 - $44,289	1,995 Added 10.15%	21,644 $248,000
Q1 2023 Apr 26, 2023	SELL	$18.7 - $23.07 $45,216 - $55,783	-2,418 Reduced 10.96%	19,649 $395,000

Q4 2022 Jan 20, 2023	SELL	$18.12 - $27.32 $8,480 - $12,785	-468 Reduced 2.08%	22,067 $0
Q3 2022 Oct 28, 2022	SELL	$16.98 - $25.54 $20,291 - $30,520	-1,195 Reduced 5.04%	22,535 $423,000
Q2 2022 Jul 26, 2022	SELL	$13.15 - $20.45 $48,102 - $74,806	-3,658 Reduced 13.36%	23,730 $442,000
Q1 2022 Apr 28, 2022	SELL	$14.54 - $21.5 $67,654 - $100,039	-4,653 Reduced 14.52%	27,388 $495,000
Q4 2021 Feb 04, 2022	BUY	$20.24 - $36.01 $648,509 - $1.15 Million	32,041 New	32,041 $665,000

148

34M

1.07M

603K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $312M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.